reports
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - April 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry un...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory ph...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in mo...
Communiqué de presse : Présentation à l’ATS et publication dans le NEJ...
Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO Les résultats de l’étude NOTUS confirment les données décisives de l’étude de phase III BOREAS et montrent que, dans le traitement de la bronchopneumopathie chronique obstructive (BPCO) avec signature inflammatoire de ty...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B share...
Television Francaise(TF1): 1 director
A director at Television Francaise(TF1) bought 37,000 shares at 8.763EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
- Stephane Beyazian
- Stephane Beyazian
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officially in competition with Hemlibra
>Positive results for the FRONTIER2 trial evaluating Mim8 in haemophilia A - Novo reported yesterday evening the clinical results of its phase 3 trial evaluating Mim8 in haemophilia A. Some 250 patients with haemophilia A and with or without inhibitors were included in the trial. The primary endpoint was to demonstrate control of bleeding episodes. Note that this trial was structured between 2 patient cohorts: one with no initial prophylaxis treatment treatment (n=57)...
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Mim8 officiellement en concurrence avec Hemlibra
>Résultats positifs de l’essai FRONTIER2 évaluant Mim8 en hémophilie A - Novo publiait hier soir les résultats cliniques de son essai de phase 3 évaluant Mim8 en hémophilie A. 250 patients atteints d’hémophilie A présentant ou non des inhibiteurs étaient inclus dans cet essai. Le critère primaire est de démontrer un contrôle des saignements. Il faut noter que cet essai a été structuré entre 2 cohortes de patients : l’une ayant initialement aucune prophylaxie (n=57) et...
- Dominic Rose
- Naresh Chouhan
AZN - The Path to 2030 Revenue of >$80bn (BUY, TP £140 [£125], 12pgs)
There has been much investor discussion of the upside potential to consensus that could happen as a result of new long-term revenue guidance at the CMD next Tuesday. We show on a product-by-product basis how Total Revenues could exceed $80bn by 2030. This would imply a 25% U/G to consensus revenue forecasts & considerably more to EPS. We do however caution investors that to get to this revenue forecast, it will require considerable R&D investment and we do not believe that consensus has factored...
Fagron shareholders approve all voting items at AGM and EGM
Fagron shareholders approve all voting items at AGM and EGM Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders and extraordinary general meeting of shareholders today. Both meetings approved all. voting items. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30 per share for the fiscal year 20...
Aandeelhouders Fagron keuren alle stempunten AVA en BAVA goed
Aandeelhouders Fagron keuren alle stempunten AVA en BAVA goed Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 13 mei 2024 – 19:00u CET Aandeelhouders Fagron keuren alle stempunten AVA en BAVA goed Fagron, de toonaangevende mondiale speler in farmaceutische bereidingen, hield vandaag haar jaarlijkse algemene vergadering van aandeelhouders en buitengewone algemene vergadering van aandeelhouders. Beide vergaderingen keurden alle voorgelegde besluiten goed. BesluitenDe algemene jaarvergadering heeft onder andere Fagron’s jaarrekening en het dividendvoorstel van €0,30 per ...
Informations relatives au nombre total de droits de vote et d’actions ...
Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 13 mai 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulation immunitaire en immuno-oncologie et en immuno-inflammation, info...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superi...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatm...
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2....
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Paris, May 13, 2024. As the largest private contributor to the security and independence of France's health ecosystem, Sanofi today announces an investment of more than €1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) a...
Press Release: Sanofi and Novavax announce co-exclusive licensing agre...
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with ...
Communiqué de presse : Sanofi et Novavax concluent un accord de licenc...
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la puissance commerciale des deux entreprises, permettra aux patients de bénéficier à partir de 2025 d’un meilleur accès à un vaccin adjuvanté à base de protéines, non-ARNm, contre la COVID-19 Accélération du ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by...
- Gerardo Ibanez
- Steven Boumans
ODDO BHF Small & MIDCAP MORNING NEWS - 05/08/2024 Date Performance sin...
Unifiedpost is a niche SaaS player in the e-invoicing and procurement channel space. Regulatory headwinds mean this market is ripe for growth, which should benefit Unifiedpost. Due to some unsuccessful past M&A, the company is in a challenging financial position today. However, it has recently embarked on a divestment path, aiming to streamline the business and improve its fundamentals. We like the new direction, however prefer to take a wait-and-see approach. - ...
OUT1V OUTOKUMPU OYJ
ZIL2 ELRINGKLINGER AG
SBMO SBM OFFSHORE NV
EURN EURONAV NV
LEI LEIFHEIT AG
LXS LANXESS AG
KCO KLOECKNER & CO SE
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
MAREL MAREL HF.
NDA AURUBIS AG
MONT MONTEA SCA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
TLGO TALGO SA
RUI RUBIS SCA
B4B METRO AG
S92 SMA SOLAR TECHNOLOGY AG
INS INSTONE REAL ESTATE GROUP AG
JEN JENOPTIK AG
CLA CLARANOVA SE
HAG HENSOLDT AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
KTA KNAUS TABBERT
SFQ SAF-HOLLAND SE
AERO MONTANA AEROSPACE AG
YOU ABOUT YOU HLDG AG
SYAB SYNLAB AG
ALVGO VOGO SA
STM STABILUS SE
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.